



(11) **EP 1 389 203 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**C07D 403/04** <sup>(2006.01)</sup> **C07D 209/48** <sup>(2006.01)</sup>  
**A61K 31/454** <sup>(2006.01)</sup> **A61K 31/4035** <sup>(2006.01)</sup>  
**A61K 31/402** <sup>(2006.01)</sup> **A61K 31/513** <sup>(2006.01)</sup>  
**A61P 43/00** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**10.03.2010 Bulletin 2010/10**

(86) International application number:  
**PCT/US2002/005868**

(45) Date of publication and mention  
of the grant of the patent:  
**02.12.2009 Bulletin 2009/49**

(87) International publication number:  
**WO 2002/068414 (06.09.2002 Gazette 2002/36)**

(21) Application number: **02780964.9**

(22) Date of filing: **26.02.2002**

---

(54) **ANALOGS OF THALIDOMIDE AS ANGIOGENESIS INHIBITORS**  
ANALOGA VON THALIDOMID ALS ANGIOGENESEINHIBITOREN  
ANALOGUES DE THALIDOMIDE UTILISES COMME INHIBITEURS DE L'ANGIOGENESE

---

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE TR**

- **HECKER, Thomas**  
**99094 Erfurt (DE)**
- **HAUSCHILDT, Sunna**  
**04229 Leipzig (DE)**

(30) Priority: **27.02.2001 US 271941 P**

(43) Date of publication of application:  
**18.02.2004 Bulletin 2004/08**

(74) Representative: **Gowshall, Jonathan Vallance**  
**Forrester & Boehmert**  
**Pettenkofenstrasse 20-22**  
**80336 München (DE)**

(73) Proprietor: **The Government of the United States**  
**of America,**  
**represented by The Secretary Department of**  
**Health**  
**and Human services**  
**Rockville, MD 20852 (US)**

(56) References cited:  
**EP-A- 0 856 513 WO-A-94/20085**  
**WO-A-97/37988 WO-A-98/03502**

(72) Inventors:

- **FIGG, William, D.**  
**Fairfax, VA 22030 (US)**
- **EGER, Kurt**  
**72072 Tuebingen (DE)**
- **TEUBERT, Uwe**  
**31789 Hameln (DE)**
- **WEISS, Michael**  
**06571 Wiehe-Garnbach (DE)**
- **GUETSCHOW, Michael,**  
**Pharmazeutisches Institut**  
**53115 Bonn (DE)**

- **GÜTSCHOW M ET AL: "Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro." BIOORGANIC & MEDICINAL CHEMISTRY. ENGLAND APR 2001, vol. 9, no. 4, April 2001 (2001-04), pages 1059-1065, XP002207264 ISSN: 0968-0896**
- **TEUBERT U ET AL: "5'-SUBSTITUTED THALIDOMIDE ANALOGS AS MODULATORS OF TNF-ALPHA" ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, vol. 331, no. 1, 1998, pages 7-12, XP002072713 ISSN: 0365-6233**

---

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

---

**EP 1 389 203 B8**